P8RI D-P8RI|cas:2147724-76-1|西域试剂

P8RI D-P8RI,98.19%

产品编号：Bellancom-P3325| CAS NO：2147724-76-1| 分子式：C₅₁H₇₇N₁₃O₉| 分子量：1016.24

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P3325		￥1200.00	杭州北京（现货）
Bellancom-P3325		￥1900.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

P8RI D-P8RI

产品介绍

P8RI (D-P8RI) 是CD31的模拟肽和 CD31 激动剂。P8RI 与 CD31 外结构域的膜旁氨基酸序列结合，通过恢复 CD31 抑制途径显示出免疫抑制作用。

生物活性

P8RI (D-P8RI) is a biomimetic peptide of CD31 and a CD31 agonist. P8RI binds to the juxtamembrane amino acid sequence of the ectodomain of CD31, shows an immunosuppressive effect through restoration of the CD31 inhibitory pathway.

体外研究

P8RI (D-P8RI) was designed as a retro-inverso peptide with all-D-amino acids allowing to maintain bioactivity and to confer resistance towards plasma proteases.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

P8RI (2.5 mg/kg; s.c.; daily from 7 to 28 after the occurrence of ADIM) prevents aneurysmal transformation by promoting the resolution of intramural hematoma and the production of collagen in dissected aortas in vivo, associated with enrichment of M2 macrophages at the site of injury.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Apo E ^-/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))
Dosage:	2.5 mg/kg
Administration:	Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II)
Result:	Aneurysmal transformation was significantly reduced.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Apo E ^-/- mice (male, 28-week-old) implanted with Ang II-releasing pumps (a model of experimental acute aortic dissection and intramural hematoma (ADIM))
Dosage:	2.5 mg/kg
Administration:	Subcutaneous injection; daily from 7 to 28 (after the implantation of the osmotic pump delivering Ang II)
Result:	Aneurysmal transformation was significantly reduced.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (98.40 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.9840 mL	4.9201 mL	9.8402 mL
5 mM	0.1968 mL	0.9840 mL	1.9680 mL
10 mM	0.0984 mL	0.4920 mL	0.9840 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶